---
title: "Valerio Therapeutics enters exclusive R&D collaboration with Abivax, secures up to €2.4 million upfront"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292860170.md"
description: "Valerio Therapeutics has entered a binding term sheet for an exclusive global R&D collaboration with Abivax focused on immune-mediated inflammatory diseases. Valerio will receive up to €2.4 million upfront, plus potential development milestones and royalties. The partnership covers candidate identification through preclinical testing, with Abivax holding options for further development. This non-dilutive funding supports Valerio's precision RNA pipeline, though definitive agreements are pending."
datetime: "2026-07-16T06:11:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292860170.md)
  - [en](https://longbridge.com/en/news/292860170.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292860170.md)
generator: "portal-rs"
---

# Valerio Therapeutics enters exclusive R&D collaboration with Abivax, secures up to €2.4 million upfront

-   Valerio Therapeutics entered a binding term sheet with Abivax for an exclusive global R&D collaboration in immune-mediated inflammatory diseases. \* Valerio to receive upfront payment up to EUR 2.4 million; eligible for development and commercial milestones plus royalties on net sales. \* Collaboration covers identification, design, manufacturing, preclinical testing of candidates; Abivax may take selected programs into further development. \* Definitive co-ownership and license agreement still pending; transaction positioned as non-dilutive funding for Valerio’s precision RNA pipeline. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valerio Therapeutics SA published the original content used to generate this news brief on July 16, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [ABVX.US](https://longbridge.com/en/quote/ABVX.US.md)

## Related News & Research

- [Corvus publishes final Phase 1/1b soquelitinib data in Blood supporting Phase 3 relapsed/refractory PTCL trial](https://longbridge.com/en/news/297177476.md)
- [Agenus reports 21.2-month median survival in Phase 1b BOT+BAL study for MSS metastatic colorectal cancer](https://longbridge.com/en/news/297338792.md)
- [Circio partners with Full Circles Therapeutics on non-viral in vivo cell therapy research](https://longbridge.com/en/news/297035152.md)
- [SynAct Pharma Expands Resomelagon’s Potential With New Preclinical Inflammation Data](https://longbridge.com/en/news/297303959.md)
- [Revolution Medicines’ Pancreatic Cancer Drug Approval Validates Microcap Propanc Biopharma’s Breakthrough Survival Results](https://longbridge.com/en/news/297207596.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**